Antimalarial activity of alkaloids isolated from Stephania rotunda

Chea, Aun; Hout, Sotheara; Bun, Sok Siya; Tabatadze, Nino; Gasquet, M.; Azas, Nadine; Élias, Riad; Balansard, G.

doi:10.1016/j.jep.2007.02.005

Cited by 44 publications

(50 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results for CN at a dose of 10 mg/kg showed a decrease of 47% of parasitaemia by intra-peritoneal injection and 50% of parasitaemia by oral administration. Drug interaction of chloroquine (CL) and major alkaloids indicates that CN-CL and TN-XN associations are synergistic (Chea et al, 2007). The bisbenzylisoquinoline alkaloids from S. erecta Craib and tetrahydroprotoberberine alkaloids from S. pierrei Diels showed anti-malarial activity against the D6 (ED, 1540 ng/mL) and W2 (ED, 3130 ng/mL) strains of Plasmodium falciparm having ED values of 950 and 470 ng/mL in the D6 and W2 strains, respectively.…”

Section: Anti-malarial Activitymentioning

confidence: 99%

The genus Stephania (Menispermaceae): Chemical and pharmacological perspectives

Semwal¹,

Badoni

Semwal

et al. 2010

Journal of Ethnopharmacology

129

View full text Add to dashboard Cite

Section: Anti-malarial Activitymentioning

confidence: 99%

The genus Stephania (Menispermaceae): Chemical and pharmacological perspectives

Semwal¹,

Badoni

Semwal

et al. 2010

Journal of Ethnopharmacology

129

View full text Add to dashboard Cite

“…CEP lessens the inflammation and pain caused by snake bites (2). CEP, or extracts from the plant, are widely used (primarily in Japan) to treat a variety of acute and chronic diseases such as alopecia areata (8), radiotherapy-induced leucopenia (9), malaria (10), and septic shock (11). Despite its use in treating a diverse number of illnesses, CEP does not have the ability to neutralize circulating venom (12,13).…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy of Antivenom and Cepharanthine for the Treatment of Mamushi (Gloydius blomhoffii) Bites in Tertiary Care Centers in Japan

et al. 2013

View full text Add to dashboard Cite

SUMMARY: To our knowledge, no one has conducted a multi-center trial evaluating the efficacy of antivenom and cepharanthine (CEP) for the treatment of mamushi (Gloydius blomhoffii) bites. Thus, we conducted a large-scale survey among tertiary care centers in Japan from November 2009 to October 2010 to evaluate the efficacy of antivenom and CEP for the treatment of mamushi bites. We divided the therapeutic interventions received by patients into 4 groups: CEP, antivenom, both CEP and antivenom, and neither CEP nor antivenom. We collected data on age, sex, comorbidities, laboratory measurements, length of hospital stay, and grades of mamushi bites (indication of bite severity ranged from I [mild] to V [severe]). We sent questionnaires to 219 tertiary care centers, of which 114 (52.1z) returned completed questionnaires. Two hundred and thirty-four cases of mamushi bites were reported. Among the severe cases (grades of mamushi bites III, IV, and V), patients administered antivenom had a significantly shorter length of hospital stay than those administered CEP ( P ＝ 0.024). In contrast, there was no significant difference in the length of hospital stay between mild cases (grades of mamushi bites I and II) ( P ＝ 0.77). Our results show that antivenom is effective in reducing the length of hospital stay in patients with severe mamushi bites.

show abstract

“…Thus, the development of new antimalarial pharmacotherapy is necessary. Many different classes of natural products, such as terpenes (Meshnick 2002), flavonoids (Auffret 2007;Froelich et al 2007), and alkaloids (Chea et al 2007), have been studied regarding antimalarial activity. This study aimed at evaluating the antimalarial activity of betulinic acid and its derivatives against chloroquine-resistant P. falciparum parasites in vitro and Plasmodium berghei parasites in vivo.…”

Section: Introductionmentioning

confidence: 99%

Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice

et al. 2009

View full text Add to dashboard Cite

Malaria is one of the most important tropical diseases and mainly affects populations living in developing countries. Reduced sensitivity of Plasmodium sp. to formerly recommended antimalarial drugs places an increasing burden on malaria control programs as well as on national health systems in endemic countries. The present study aims to evaluate the antimalarial activity of betulinic acid and its derivative compounds, betulonic acid, betulinic acid acetate, betulinic acid methyl ester, and betulinic acid methyl ester acetate. These substances showed antiplasmodial activity against chloroquine-resistant Plasmodium falciparum parasites in vitro, with IC(50) values of 9.89, 10.01, 5.99, 51.58, and 45.79 microM, respectively. Mice infected with Plasmodium berghei and treated with betulinic acid acetate had a dose-dependent reduction of parasitemia. Our results indicate that betulinic acid and its derivative compounds are candidates for the development of new antimalarial drugs.

show abstract

Antimalarial activity of alkaloids isolated from Stephania rotunda

Cited by 44 publications

References 15 publications

The genus Stephania (Menispermaceae): Chemical and pharmacological perspectives

The genus Stephania (Menispermaceae): Chemical and pharmacological perspectives

Clinical Efficacy of Antivenom and Cepharanthine for the Treatment of Mamushi (Gloydius blomhoffii) Bites in Tertiary Care Centers in Japan

Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice

Contact Info

Product

Resources

About